AbbVie Inc. (ABBV) Earnings History

6 quarters held0/8 transcripts analyzed1/30 figures attested
Connect your agent
PeriodRevenueYoYNet incomeEPS (dil.)Filed
Q2 2026$17.0B+10.2%$3.6B$2.03Jul 31, 2026
LATEST10-QFiled Jul 31, 2026, 7:51 AM ET
Earnings call · Jul 31, 2026
Q2 FY26YoY6M FY26
Revenue$17.0B1+10.2%$32.0B
Net income$3.6B+285.2%–
Op income$6.4B+31.4%–
EPS (dil.)$2.03+290.4%$2.42
EPS (basic)–––
Net margin21.3%+15.2pp
  1. [1] “Net Revenues (in millions) Total Reported $16,990” view source

Guidance & outlook

Management guidance

Q2 2026

fy_current

eps_diluted
$13.87—$14.07
Q1 2026$15.0B+12.4%$697.0M–Apr 29, 2026
Earnings filing (8-K)10-QFiled Apr 29, 2026, 7:50 AM ET
Earnings call · Apr 29, 2026
Q1 FY26YoY
Revenue$15.0B+12.4%
Net income$697.0M-45.8%
Op income$4.0B+6.9%
EPS (dil.)––
EPS (basic)––
Gross margin71.9%–
Op margin26.6%–
Net margin4.7%-5.0pp
Q3 2025$15.8B+9.1%$186.0M$0.10Oct 31, 2025
Earnings filing (8-K)10-QFiled Oct 31, 2025, 7:51 AM ET
Q3 FY25YoY9M FY25
Revenue$15.8B+9.1%$44.5B
Net income$186.0M-87.9%$2.4B
Op income$1.9B-50.3%$10.5B
EPS (dil.)$0.10-88.6%$1.34
EPS (basic)–––
Gross margin66.4%–
Op margin12.1%-14.4pp
Net margin1.2%-9.6pp
Q2 2025$15.4B+6.6%$938.0M$0.52Jul 31, 2025
Earnings filing (8-K)
Q2 FY25YoY6M FY25
Revenue$15.4B+6.6%$28.8B
Net income$938.0M-31.5%$2.2B
Op income$4.9B+22.4%$8.6B
EPS (dil.)$0.52-32.5%$1.24
EPS (basic)–––
Gross margin71.8%–
Op margin31.7%–
Net margin6.1%-3.4pp
Q1 2025$13.3B+8.4%$1.3B$0.72Apr 25, 2025
Earnings filing (8-K)
Q1 FY25YoY
Revenue$13.3B+8.4%
Net income$1.3B-6.1%
Op income$3.7B+33.4%
EPS (dil.)$0.72-6.5%
EPS (basic)$0.72-6.5%
Gross margin70.0%–
Op margin28.0%–
Net margin9.6%-1.5pp
Q4 2024$15.1B+5.6%$-22.0M$-0.02Jan 31, 2025
Earnings filing (8-K)
Q4 FY24YoYFY24
Revenue$15.1B+5.6%$56.3B
Net income$-22.0M–$4.3B
Op income$-1.5B–$9.1B
EPS (dil.)$-0.02–$2.39
EPS (basic)–––
Gross margin70.9%–
Op margin-9.9%–
Net margin-0.1%-5.9pp

IR event calendar

This company's IR event calendar has not been harvested yet — an empty result here does NOT mean the company has no IR events.

Filing coverage

79 filings indexed · 62,400 XBRL facts
FilingDatePeriodSectionsTables
8-K2026-08-05–20
10-Q2026-08-03–3158
8-K2026-07-31Q2 202670
8-K2026-07-06Q2 202640
8-K2026-06-22–10
8-K2026-05-12–10
10-Q2026-05-08–3146
8-K2026-04-29Q1 202660
8-K2026-04-03Q1 202630
DEF 14A2026-03-23–360

Showing the latest 10 of 79 — the full set is in the API.

Related Research

Analysis

The $15 Billion Earnings Illusion Behind AbbVie's 96x P/E

Analysis

Boston Scientific Hit a ROIC Inflection — Then Bet $14.5B on Penumbra

Analysis

Four Forces Are Manufacturing Regeneron's EPS Growth as Operations Decline